The dangerous shortcut is to see severe aortic stenosis (AS), microcytosis, and a low ferritin and immediately write “Heyde syndrome.” That may ultimately be correct, but it is not the starting diagnosis.
The more useful clinical question is: What has been established, what remains a hypothesis, and which decisions cannot wait while the anemia is investigated?
Consider this illustrative case: a 79-year-old man with four months of progressive exertional dyspnea and two brief episodes of near-syncope while doing yard work. He describes vague chest pressure on inclines but denies melena or hematochezia. Hemoglobin is 82 g/L, MCV 78 fL, and ferritin 15 micrograms/L. Echocardiography shows an aortic valve area of 0.7 cm², mean gradient 48 mmHg, peak velocity 4.5 m/s, and preserved LVEF.
His baseline functional history still matters: walking distance, stair tolerance, orthopnea, nocturnal symptoms, and whether the episodes occurred only during exertion. Those details help determine whether the valve is clinically symptomatic, whether anemia is amplifying the presentation, or whether another process is contributing.
Start by separating two diagnoses
The echocardiogram establishes high-gradient severe AS: the valve area, mean gradient, and peak velocity are all in the severe range. Exertional dyspnea, chest pressure, and syncope or presyncope are concerning symptoms in that setting. The patient should be treated as having symptomatic severe AS pending multidisciplinary valve assessment, not as someone with an incidental murmur discovered during an anemia workup.
The laboratory pattern separately establishes iron-deficiency anemia. A low ferritin with microcytosis strongly supports depleted iron stores. It does not identify the source of iron loss.
These conditions interact physiologically. A hypertrophied left ventricle already has limited ability to increase forward flow across a fixed obstruction. Reduced oxygen-carrying capacity can worsen exertional myocardial and cerebral oxygen delivery. But anemia does not explain the high transvalvular gradient or fixed outflow obstruction.
| Finding | What it establishes | What it does not establish |
|---|---|---|
| AVA 0.7 cm², mean gradient 48 mmHg, velocity 4.5 m/s | High-gradient severe AS | That every symptom is caused only by the valve |
| Hemoglobin 82 g/L, microcytosis, ferritin 15 | Iron-deficiency anemia | The location or cause of blood loss |
| Severe AS plus iron deficiency | A possible link through occult GI bleeding and acquired VWF dysfunction | Confirmed Heyde syndrome |
The Heyde hypothesis is narrower than many stems imply
The classic construct of Heyde syndrome is the coexistence of significant AS, gastrointestinal bleeding—often from angiodysplasia—and acquired von Willebrand syndrome (AVWS). Iron-deficiency anemia may be the presenting consequence, but anemia alone does not establish the syndrome; it should prompt evaluation for a gastrointestinal bleeding source and, when clinically relevant, AVWS.
The proposed mechanism is shear-related loss of high-molecular-weight von Willebrand factor multimers across the stenotic valve. This can impair primary hemostasis and promote bleeding from fragile gastrointestinal vascular lesions. The acquired disorder resembles, but is not identical to, inherited type 2A von Willebrand disease.
Testing may include von Willebrand factor antigen, activity, factor VIII, and multimer analysis when recurrent or unexplained bleeding makes AVWS clinically relevant. Loss of high-molecular-weight multimers supports the diagnosis, but these tests do not localize a bleeding lesion and should not replace gastrointestinal evaluation.
A normal platelet count or routine coagulation profile also does not exclude a primary-hemostasis defect involving von Willebrand factor. Conversely, an abnormal VWF result does not prove that a patient’s anemia is caused by angiodysplasia. The clinical phenotype and bleeding evaluation still matter.
Investigate the anemia without waiting for overt bleeding
In an older man with confirmed iron-deficiency anemia, absence of visible blood is not reassuring enough to stop the workup. Ask about:
- melena, hematochezia, prior stool blood testing, change in bowel habits, early satiety, and unintentional weight loss;
- aspirin, nonsteroidal anti-inflammatory drugs, antiplatelets, anticoagulants, and supplements;
- prior colonoscopy or upper endoscopy and the quality and timing of those studies;
- diet, prior gastrointestinal surgery, chronic diarrhea, and celiac disease risk; and
- family history of colorectal cancer or other gastrointestinal disease.
A practical evaluation usually includes repeat CBC and iron studies, renal and hepatic function, reticulocyte response, and a smear when the pattern is atypical or more than one process may be present. Additional testing should be guided by the history rather than ordered as a reflexive panel.
For asymptomatic adult men with iron-deficiency anemia, current gastroenterology guidance generally favors bidirectional endoscopy—upper endoscopy and colonoscopy—over iron replacement alone. If bidirectional endoscopy is unrevealing, noninvasive testing for Helicobacter pylori is suggested; celiac serology is appropriate when celiac disease is clinically plausible. In uncomplicated cases with negative bidirectional endoscopy and no other identified source, a trial of iron replacement is generally considered before routine capsule endoscopy, while persistent or recurrent anemia should prompt reassessment and escalation.
The differential remains broader than angiodysplasia: colorectal or upper gastrointestinal malignancy, peptic ulcer disease, medication-related mucosal injury, inflammatory disease, malabsorption, and nutritional deficiency may all coexist with AS.
Stabilize the patient without making transfusion the treatment plan
A hemoglobin of 82 g/L in a patient with severe AS deserves attention, but it does not automatically justify transfusion to a target above 90–100 g/L. Contemporary transfusion guidance favors a restrictive approach for most hemodynamically stable adults and allows consideration of transfusion around 80 g/L in patients with preexisting cardiovascular disease, while emphasizing symptoms and the overall clinical context.
If the patient has ongoing ischemic chest pain, dynamic ECG changes, hypotension, active bleeding, or symptoms clearly attributable to anemia, the decision becomes individualized and urgent. The appropriate response is not to apply a memorized liberal threshold, but to reassess perfusion, bleeding, ischemia, volume status, and the expected benefit and harm of transfusion. Transfusion also adds volume, so assess congestion and use the smallest effective amount when transfusion is chosen.
Iron replacement addresses the deficit but does not correct the valve or identify the source of blood loss. It should therefore proceed alongside, not instead of, valve and gastrointestinal planning.
Do not postpone valve assessment until the anemia is “fixed”
Symptomatic severe AS is a time-sensitive structural heart problem. Correcting iron deficiency may improve exercise tolerance, but it does not remove the fixed obstruction responsible for exertional syncope or low-flow symptoms. In a stable patient without uncontrolled major bleeding, valve-team evaluation and anemia investigation should proceed in parallel.
The choice between transcatheter and surgical replacement should not be made from age or anemia alone. Current guidance emphasizes Heart Team assessment of symptoms, life expectancy, frailty, surgical risk, vascular access, valve anatomy, lifetime management, and patient preferences. Anemia may alter procedural preparation and bleeding-risk planning, but it is not by itself an automatic indication for TAVR.
When true Heyde syndrome is present, valve replacement often improves the acquired bleeding tendency and reduces recurrent gastrointestinal bleeding. The benefit is incomplete in some patients, particularly when residual valve disease remains. Recurrent iron deficiency after intervention therefore still requires follow-up rather than being dismissed as an expected postoperative problem.
Common traps on rounds and examinations
- Calling AS plus low ferritin Heyde syndrome. This is a working hypothesis until the gastrointestinal and bleeding phenotype supports it.
- Assuming no melena means no GI blood loss. Chronic occult bleeding can present only as iron depletion.
- Letting a normal platelet count end the hemostasis discussion. AVWS is a qualitative VWF problem, not necessarily a platelet-count problem.
- Correcting the hemoglobin while delaying valve referral. Transfusion or iron may improve oxygen delivery without correcting the obstructive lesion.
- Choosing TAVR solely because the patient is older and anemic. The intervention must be individualized by a valve team.
Practical takeaways
- Exertional syncope with concordant high-gradient severe AS is a high-priority, time-sensitive valve problem, even when the patient appears comfortable at rest.
- Ferritin and red-cell indices establish iron deficiency; they do not establish its source.
- Heyde syndrome is more than a memorable association: think AS, GI bleeding or angiodysplasia, and acquired VWF dysfunction.
- In an older man with iron-deficiency anemia, pursue gastrointestinal evaluation even without visible bleeding.
- Do not transfuse to an arbitrary hemoglobin target; integrate ischemia, symptoms, hemodynamics, active bleeding, and cardiovascular disease.
- Coordinate anemia treatment, GI evaluation, and valve intervention rather than allowing one workup to indefinitely delay the others.
